Neurocrine Biosciences, Inc. (NBIX)
127.68
-2.02
(-1.56%)
USD |
NASDAQ |
Mar 20, 16:00
127.68
0.00 (0.00%)
After-Hours: 20:00
Neurocrine Biosciences Research and Development Expense (Quarterly) : 258.20M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Glaukos Corp. | 43.65M |
| Edgewise Therapeutics, Inc. | 43.07M |
| Nuvalent, Inc. | 67.80M |
| Agenus, Inc. | 7.511M |
| Curis, Inc. | 5.825M |